<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601688</url>
  </required_header>
  <id_info>
    <org_study_id>ME-260620</org_study_id>
    <nct_id>NCT04601688</nct_id>
  </id_info>
  <brief_title>Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.</brief_title>
  <official_title>Study on Branch Retinal Vein Occlusion Patients Receiving Bevacizumab and Dexamethasone or Bevacizumab Only on Naive Eyes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>He Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>He Eye Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the visual outcome and prognostic factors after&#xD;
      intraocular injections of Bevacizumab or combination of Bevacizumab And Dexamethasone under&#xD;
      pro re nata treatment regimen for Branch Retinal Vein Occlusion (BRVO) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the clinical outcome after intraocular injections of&#xD;
      Bevacizumab or combination of Bevacizumab and Dexamethasone under pro re nata treatment&#xD;
      regimen for the patients with Branch Retinal Vein Occlusion (BRVO) patients. Mean change of&#xD;
      logarithm of the minimal angle of resolution (logMAR) visual acuity (VA), central foveal&#xD;
      thickness (CFT), contrast sensitivity (CS) as well as predictive factors including&#xD;
      best-corrected visual acuity (BCVA), vision related questionnaires and various other ocular&#xD;
      parameters will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2020</start_date>
  <completion_date type="Anticipated">September 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in monocular BCVA in the treatment eye</measure>
    <time_frame>Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Monocular BCVA in the treatment eye is assessed by using ETDRS visual acuity charts at 4 meters is assessed and compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in binocular BCVA</measure>
    <time_frame>Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Binocular BCVA is assessed by using ETDRS visual acuity charts at 4 meters is assessed and compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in central subfield retinal thickness</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Mean change in central subfield retinal thickness in the study eye, as determined by spectral domain optical coherence tomography (OCT) is assessed and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Humphrey 10-2 visual field in the treatment eye</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Mean deviation (MD) of the Humphrey 10-2 visual field is assessed by a Humphrey 10-2 visual field test and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bevacizumab. Treatments</measure>
    <time_frame>Day 1 through Month 6</time_frame>
    <description>Number of injections provided to the patients during the 6 month period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in NEI VFQ25</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Scores from NEI VFQ25 questionnaire is assessed and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in EQ-5D 5L</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Scores from EQ-5D 5L questionnaire is assessed and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in VisQoL scores</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Scores from VisQoL questionnaire is assessed and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in wavefront aberrations</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Mean deviation (MD) of wavefront aberrations is assessed by Nidek OPD Scan III and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in ocular surface and tear-film</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Mean deviation (MD) of ocular surface and tear-film parameters is assessed by Oculus Keratographer test and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in vessel density</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Mean deviation (MD) of vessel density is assessed by Spectralis OCT2, Heidelberg-Engineering test and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Side effects are measured by a review of the participant's medical and ophthalmic history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>People meeting driving standards</measure>
    <time_frame>Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.</time_frame>
    <description>Percentage (%) of people meeting driving standards is assessed by an Esterman binocular visual field test and compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>BRVO: Bevacizumab and intravitreal Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRVO: Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with BRVO will receive Bevacizumab only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab Ophthalmic and Intravitreal Dexamethasone</intervention_name>
    <description>Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.</description>
    <arm_group_label>BRVO: Bevacizumab and intravitreal Dexamethasone</arm_group_label>
    <other_name>Avastin®</other_name>
    <other_name>Ozurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab Ophthalmic</intervention_name>
    <description>Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.</description>
    <arm_group_label>BRVO: Bevacizumab</arm_group_label>
    <other_name>Avastin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained before any study assessment is performed&#xD;
&#xD;
          2. Diagnosis of visual impairment exclusively due to ME secondary to BRVO&#xD;
&#xD;
          3. BCVA score at Screening and Baseline between 10/40 (0.5) to 20/400 (0.05) on the&#xD;
             Snellen chart.&#xD;
&#xD;
          4. Central foveal thickness (CFT) ≥ 300 µm&#xD;
&#xD;
          5. Naive Eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing (lactating) women&#xD;
&#xD;
          2. Stroke or myocardial infarction less than 3 months before Screening&#xD;
&#xD;
          3. Uncontrolled blood pressure defined as systolic value of &gt;160 mm Hg or diastolic value&#xD;
             of &gt;100 mm Hg at Screening or Baseline.&#xD;
&#xD;
          4. Any active periocular or ocular infection or inflammation at Screening or Baseline in&#xD;
             either eye&#xD;
&#xD;
          5. Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before&#xD;
             Baseline in either eye&#xD;
&#xD;
          6. Neovascularization of the iris or neovascular glaucoma in the study eye&#xD;
&#xD;
          7. Use of any systemic or ocular antivascular endothelial growth factor (anti-VEGF) drugs&#xD;
             within 6 months before Baseline&#xD;
&#xD;
          8. Panretinal laser photocoagulation performed, anticipated or scheduled in the study eye&#xD;
&#xD;
          9. Focal or grid laser photocoagulation in the study eye&#xD;
&#xD;
         10. Use of intra- or periocular corticosteroids (including sub-Tenon) or ocular anti-VEGF&#xD;
             treatment within 3 months before Screening in the study eye&#xD;
&#xD;
         11. Any use of intraocular corticosteroid implants (eg, dexamethasone [Ozurdex®],&#xD;
             fluocinolone acetonide [Iluvien®]) in the study eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei He</last_name>
    <role>Study Chair</role>
    <affiliation>He Eye Specialist Hospital, Shenyang.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>He Eye Specialist Hospital, Shenyang.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel E Pazo</last_name>
    <role>Study Director</role>
    <affiliation>He Eye Specialist Hospital, Shenyang.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li, M.D., Ph.D.</last_name>
    <phone>0086-15104083505</phone>
    <email>robin_lijun@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuel E Pazo</last_name>
    <phone>0086-18612782131</phone>
    <email>ericpazo@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>He Eye Specialist Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Li, M.D., Ph.D.</last_name>
      <phone>0086-15104083505</phone>
      <email>robin_lijun@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel Eric Pazo, M.D., Ph.D.</last_name>
      <phone>0086-18612782131</phone>
      <email>ericpazo@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qiqi Zhong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lanting Yang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

